An observational study in Ventricular Fibrillation, Ventricular Arrythmia and Polymorphic Ventricular Tachycardia, sponsored by Maastricht University Medical Center. Status unknown at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-07.
Sponsored by Maastricht University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Ventricular Fibrillation with a site in Netherlands — 6 open to participants now, 6 under way, 1 of them phase 3. Ventricular Fibrillation · Netherlands.
Among the 17 studies in Ventricular Fibrillation with a site in Netherlands, this one is the only one that started in 2019, is one of 6 observational ones, and was the 11th registered.
186 studies on the registry are indexed under Ventricular Fibrillation; 37 are open to participants now.
Browse Ventricular Fibrillation studies →6 of the 17 studies in Ventricular Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:
Catharina Ziekenhuis Eindhoven · Sites in Netherlands
Ages 18+
AtaCor Medical, Inc. · Sites in Netherlands, United States
Ages 18+
Gabriel Riva · Sites in Netherlands, Spain, Sweden
Ages 18+
Catharina Ziekenhuis Eindhoven · Sites in Netherlands
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 22 Ventricular Fibrillation studies recruiting now, 19 (86%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 450 across 82 observational studies indexed under Ventricular Fibrillation.
Median enrollment 280 across the 11 interventional studies, 401 across the 6 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
Maastricht University Medical Center has 2 studies filed under Ventricular Fibrillation — fewer than ten, so there is no comparison to draw.
1 of the studies in Ventricular Fibrillation with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07324031AtaCor Medical, Inc.Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Ventricular Fibrillation with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the electrophysiological properties of the heart conduction system in patients with unexplained polymorphic ventricular tachycardia (VT) and/or ventricular fibrillation (VF), in patients with specific genetic mutations regarding sudden cardiac death or sudden cardiac arrest, in their family members and in a control cohort. The electrophysiological properties will be measured with the relatively new technique ECG-Imaging (ECGI).
Also a National Dutch registry for patients with unexplained polymorphic VT and/or VF and their family members will be created.
By combining the data from the registry and the results of ECGI, The investigators hope to identity risk markers for patients at higher risk for apparently idiopathic ventricular fibrillation, and use these for an adapted flow chart for the 'general'population of patients at risk for unexplained polymorphic VT and/or VF. The investigators aim to be able to identify patients before the first arrhythmic event, and aim for better treatment strategies in the future.
ECGI combines electrical body-surface mapping with 256 electrodes placed on the thorax with a CT-scan obtaining the anatomy of the heart and torso, hereby able to reconstruct local electrograms, activation and recovery times. In recent research, ECGI provided numerous extra insights into normal cardiac electrophysiology, but also electrophysiological disorders and disease. The results strongly suggest that ECGI can play a pivotal role in further characterizing arrhythmia mechanisms, therefore could do so for polymorphic VT or idiopathic VF leading to diagnosis and treatment improvement. Moreover, ECGI seems to have the potential to detect arrhythmogenic substrate in individuals before their first event, offering the possibility to diagnose and treat patients before sudden cardiac arrest occurs.
In the VIGILANCE study:
ECGI will be used to noninvasively characterize the epicardial electrophysiological substrate and triggers of:
patients seen at the outpatient clinic at the department of cardiology or (cardio)genetics, patients admitted to the ward of cardiology or the intensive care unit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, a subject must be ≥ 18 years old and meet one of the following criteria:
Control subjects with structurally normal hearts with a clinical indication for a cardiac CT scan.
Family members must be in adequate health to be able to travel to the hospital for research purposes.
3rd degree family members can also be contacted as described in chapter 11.2.2 if at least one of the following criteria is met:
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Subject has an estimated (eGFR) of \<30mL/min/1.73m2
, using the MDRD calculation
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. Unexplained polymorphic VT and/or VF patients. 2. Patients with VF and the DPP6 risk haplotype, reported by the AUMC team. 3. The Worm population of patients with a SCN5A founder mutation and other conspiring genetic variants at MUMC+
Diagnostic Test: ECG-Imaging
Family members of index patients of group(s) mentioned above
Diagnostic Test: ECG-Imaging
Control subjects with structurally normal hearts with an indication for a cardiac CT,
Diagnostic Test: ECG-Imaging
A body surface potential mapping and a cardiac + low dose CT-scan.
ECG-Imaging outcome: epicardial potentials
reconstructed epicardial potentials, represented in mV over time(s).
Time frame: 3 years
ECG-Imaging outcome: activation and repolarization maps
Activation and repolarization maps. These are made by measuring acivation and repolarization times from the reconstructed potentials in miliseconds. Then local activation and recovery times are plotted on a CT-derived heart mesh. The entire activation and repolarization of the epicardium of the heart can be visualized this way.
Time frame: 3 years
(Possible) Prognostic risk factors for recurrent ventricular arrhythmias
possible risk factors, found in the registry, given as odds/hazard ratio.
Time frame: 3 years
Recurrence of ventricular arrhythmias
documentation over the period of follow-up, if studysubjects had a recurrence of ventricular arrythmia(s), presented as number of events over a time period.
Time frame: 3 years
Started Apr 2019 (actual). Primary completion is estimated for Apr 2023, 48 months after the start.
Of 28 observational studies under Ventricular Fibrillation, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 39. This study's planned 48 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →